NCT Number: NCT00197795
Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month Schedule to Health UK Adults
To measure the serum bactericidal antibody levels and cell mediated immune responses before and six weeks after each dose of meningococcal outer membrane vesicle vaccine given at 0,6 and 12 weeks to healthy UK adults.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–55 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Informed written consent given for three immunizations with MenBVac and five blood tests
- Between the ages of 18 and 55 years inclusive at recruitment
Exclusion criteria
- Previous history of bacteriologically confirmed meningococcal disease
- History of clinically significant allergic sensitivity to any vaccine received in the past
- Immunodeficiency
- Any other acute or chronic systemic illness or dependence or abuse of drugs or alcohol
- Language difficulties sufficient to preclude adequate comprehension of the study information
- Possibility of pregnancy
- Receipt of any other vaccine in the previous 4 weeks
- Receipt of any group B vaccine in the past
- Current participation in any other clinical trial
- Generalized acute systemic illness and/or temp >38C on day of vaccination deferral
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Public Health England
Other Gov
Registry information
Important dates
- Study start
- 2005
- Primary completion
- 2006
- Study completion
- 2006
- First posted
- Sep 20, 2005
- Registry last updated
- Aug 24, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)
NCT01621945
Neisseria Meningitidis
Neufchâtel-en-Bray, France
View Trial DetailsStudy to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers
NCT03419533
Neisseria Meningitidis
Adelaide, South Australia, Australia
View Trial DetailsInvestigating Meningococcal Vaccines in Adults
NCT02398396
Bacterial Infections, Bacterial Infections and Mycoses
Oxford, Oxfordshire, United Kingdom
View Trial DetailsStudy of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine
NCT00454987
Bacterial Infections, Bacterial Infections and Mycoses
Bydgoszcz, Poland
View Trial Details